Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC

Lorlatinib is an oral third-generation inhibitor of anaplastic lymphoma kinase (ALK) with activity in advanced ALK-positive non-small cell lung cancer (NSCLC) in both the first and subsequent line setting. Superior systemic and intracranial efficacy of lorlatinib over crizotinib, a first-generation...

Descripción completa

Detalles Bibliográficos
Autores principales: Yun, Karen M, Bazhenova, Lyudmila A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890401/
https://www.ncbi.nlm.nih.gov/pubmed/35250311
http://dx.doi.org/10.2147/CMAR.S283199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8890401/
https://www.ncbi.nlm.nih.gov/pubmed/35250311
http://dx.doi.org/10.2147/CMAR.S283199

Ejemplares similares